Phase 1/2 Study of CORT125134 in Combination With With Nab-paclitaxel in Patients With Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Relacorilant (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours
- Focus Therapeutic Use
- Sponsors Corcept Therapeutics
- 13 Mar 2018 Planned number of patients changed from 82 to 146.
- 02 Nov 2017 According to a Corcept Therapeutics media release, the company expects to open efficacy cohort in patients with pancreatic cancer by year-end.
- 23 Feb 2017 Planned End Date changed from 1 Dec 2018 to 1 Jun 2020.